Gastric cancer is the fifth most frequently diagnosed cancer worldwide and the third leading cause of cancer-related deaths [1]. Nearly two-thirds of newly diagnosed gastric cancer patients in Western countries present with advanced disease and are therefore being offered systemic treatments.
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports
Quinzii, Alberto;Zecchetto, Camilla;Casalino, Simona;Gaule, Marina;Pesoni, Camilla;Merz, Valeria;Contarelli, Serena;Pietrobono, Silvia;Melisi, Davide
2022-01-01
Abstract
Gastric cancer is the fifth most frequently diagnosed cancer worldwide and the third leading cause of cancer-related deaths [1]. Nearly two-thirds of newly diagnosed gastric cancer patients in Western countries present with advanced disease and are therefore being offered systemic treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
